WallStSmart
HURA

TuHURA Biosciences Inc

NASDAQ: HURA · HEALTHCARE · BIOTECHNOLOGY

$2.05
+0.99% today

Updated 2026-09-11

Market cap
$133.19M
P/E ratio
P/S ratio
EPS (TTM)
$-0.54
Dividend yield
52W range
$0 – $3
Volume
0.3M

TuHURA Biosciences Inc (HURA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-133.39%
ROA
-58.40%
Debt/equity
0.02x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2010$-5582.00
2011$-33136.00
2012$-18885.00
2014$-8.29M
2015$-4.35M
2016$-8.86M
2017$-8.08M
2018$-11.14M
2019$-8.05M
2020$-9.13M
2021$-38.30M
2022$0.00$-22.66M
2023$0.00$-14.65M
2024$0.00$-8.32M
2025$0.00$-21.68M
2026$0.00$-30.06M

Frequently asked questions

How much free cash flow does HURA generate?

HURA produced $-27.71M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is HURA's balance sheet healthy?

HURA holds $3.62M in cash and equivalents against — in long-term debt, on $20.93M of shareholder equity. That debt is best read against the cash flow the business throws off each year.